IRIS
Modica, Roberta
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 1.659
NA - Nord America 1.125
AS - Asia 983
SA - Sud America 88
AF - Africa 50
Continente sconosciuto - Info sul continente non disponibili 1
OC - Oceania 1
Totale 3.907
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.100
RU - Federazione Russa 1.001
SG - Singapore 493
IT - Italia 259
HK - Hong Kong 245
CN - Cina 149
DE - Germania 111
NL - Olanda 79
BR - Brasile 78
FI - Finlandia 48
GB - Regno Unito 41
IN - India 38
CI - Costa d'Avorio 37
FR - Francia 31
KR - Corea 29
CA - Canada 24
UA - Ucraina 22
SE - Svezia 17
IE - Irlanda 15
VN - Vietnam 15
AT - Austria 11
ZA - Sudafrica 10
BE - Belgio 6
CO - Colombia 6
CZ - Repubblica Ceca 5
LT - Lituania 4
PL - Polonia 3
AR - Argentina 2
AZ - Azerbaigian 2
BD - Bangladesh 2
ES - Italia 2
ID - Indonesia 2
JP - Giappone 2
KE - Kenya 2
UZ - Uzbekistan 2
AU - Australia 1
CH - Svizzera 1
CR - Costa Rica 1
EU - Europa 1
IQ - Iraq 1
JO - Giordania 1
MD - Moldavia 1
NP - Nepal 1
PE - Perù 1
PK - Pakistan 1
RS - Serbia 1
SK - Slovacchia (Repubblica Slovacca) 1
TN - Tunisia 1
VE - Venezuela 1
Totale 3.907
Salva come PNG Salva come JPEG
Città #
Singapore 306
Moscow 283
Hong Kong 245
Chandler 185
Santa Clara 144
Ashburn 128
Naples 70
Amsterdam 67
Hefei 47
Helsinki 34
Kochi 32
Seattle 30
Seoul 29
Düsseldorf 24
Millbury 23
Milan 22
Beijing 21
Frankfurt am Main 21
Des Moines 20
Napoli 19
Rome 17
Boston 15
Falkenstein 15
Jacksonville 15
Lawrence 15
Nanjing 15
Ottawa 15
London 14
Princeton 13
Dong Ket 12
Munich 12
Washington 12
Wilmington 11
Portici 10
Portsmouth 10
Los Angeles 9
Nuremberg 9
Kronberg 8
Afragola 7
Nanchang 7
Toronto 7
Brussels 6
Houston 6
São Paulo 6
The Dalles 6
Dublin 5
Lappeenranta 5
Lauterbourg 5
Paris 5
Rochdale 5
Bogotá 4
Buffalo 4
Cervinara 4
Pune 4
Turku 4
Vienna 4
Boardman 3
Brno 3
Casavatore 3
Chongqing 3
Hanoi 3
Hebei 3
Philadelphia 3
Shijiazhuang 3
Woodbridge 3
A Coruña 2
Ann Arbor 2
Baku 2
Bandung 2
Bari 2
Bicester 2
Buenos Aires 2
Cagliari 2
Campinas 2
Council Bluffs 2
Dallas 2
Fairfield 2
Genoa 2
Jundiaí 2
Kunming 2
Marcianise 2
Melzo 2
Messina 2
Mosciano Sant'Angelo 2
Nairobi 2
New York 2
Olomouc 2
Phoenix 2
Piano Di Sorrento 2
Pozzuoli 2
Redwood City 2
Riva del Garda 2
San Jose 2
Sant'Antimo 2
Scafati 2
Shenyang 2
Shenzhen 2
Solaro 2
Tappahannock 2
Torre Del Greco 2
Totale 2.168
Salva come PNG Salva come JPEG
Nome #
Potential role of cinacalcet hydrochloride in sporadic primary hyperparathyroidism without surgery indication. 90
Hepatic arterial embolization in patients with neuroendocrine tumors. 84
GLP-1: benefits beyond pancreas. 83
Quality of life in patients with neuroendocrine neoplasms: The role of severity, clinical heterogeneity and resilience 77
From microbiota toward gastro-enteropancreatic neuroendocrine neoplasms: Are we on the highway to hell? 77
Pituitary function and morphology in Fabry disease. 76
Epidemiology of pancreatic neuroendocrine neoplasms: a gender perspective 76
Emerging therapies in pheochromocytoma and paraganglioma: Immune checkpoint inhibitors in the starting blocks 76
Identification of functional pathways and molecular signatures in neuroendocrine neoplasms by multi-omics analysis 71
Immune checkpoint blockade for Merkel cell carcinoma: actual findings and unanswered questions 69
Everolimus as first line therapy for pancreatic neuroendocrine tumours: current knowledge and future perspectives 68
Second-line sunitinib as a feasible approach for iodine-refractory differentiated thyroid cancer after the failure of first-line sorafenib 67
Nutrition and neuroendocrine tumors: An update of the literature. 67
Diagnosis of Flier’s syndrome in a patient with nondiabetic hypoglycemia: a case report and critical appraisal of the literature 66
Bone metastases in neuroendocrine neoplasms: From pathogenesis to clinical management 65
Open issues on G3 neuroendocrine neoplasms: Back to the future 64
The antiproliferative effect of pasireotide LAR alone and in combination with everolimus in patients with medullary thyroid cancer: a single-center, open-label, phase II, proof-of-concept study 63
Lanreotide therapy vs active surveillance in MEN1-related pancreatic neuroendocrine tumors <2 cm 62
Pancreatic Neuroendocrine Tumors in patients with Multiple Endocrine Neoplasia Type 1: Diagnostic Value of Different MRI Sequences 62
Efficacy and Safety of Everolimus in Extrapancreatic Neuroendocrine Tumor: A Comprehensive Review of Literature 60
An incidental rectal neuroendocrine microcarcinoma ('micro-NEC') coexistent with a high grade adenoma 59
Role of contrast-enhanced ultrasound to define prognosis and predict response to biotherapy in pancreatic neuroendocrine tumors 57
The safety of available treatments options for neuroendocrine tumors 56
Neuroendocrine neoplasms in the context of inherited tumor syndromes: a reappraisal focused on targeted therapies (Oct, 10.1007/s40618-022-01905-4, 2022) 55
Vitamin D deficiency and tumor aggressiveness in gastroenteropancreatic neuroendocrine tumors 53
Therapeutic sequences in patients with grade 1−2 neuroendocrine tumors (NET): an observational multicenter study from the ELIOS group 52
A Multicenter Epidemiological Study on Second Malignancy in Non-Syndromic Pheochromocytoma/Paraganglioma Patients in Italy 50
A rare rarity: Neuroendocrine tumor of the esophagus 47
Chronotype: what role in the context of gastroenteropancreatic neuroendocrine tumors? 47
Therapeutic strategies for patients with neuroendocrine neoplasms: current perspectives 46
Health-related quality of life in patients with neuroendocrine neoplasms: a two-wave longitudinal study 46
Complete clinical and biochemical control with cabergoline and octreotide in a patient with ectopic ACTH syndrome before surgery 46
Role of Metformin on Recurrence-Free Survival in Neuroendocrine Tumors 45
Erratum to: GLP-1: Benefits beyond pancreas 45
Lipid Metabolism and Homeostasis in Patients with Neuroendocrine Neoplasms: From Risk Factor to Potential Therapeutic Target 45
Cardio-Metabolic Indices and Metabolic Syndrome as Predictors of Clinical Severity of Gastroenteropancreatic Neuroendocrine Tumors 44
Characterization of Atypical Pheochromocytomas with Correlative MRI and Planar/Hybrid Radionuclide Imaging: A Preliminary Study 42
ASO Visual Abstract: Radical Resection in Enteropancreatic Neuroendocrine Tumors-Recurrence-Free Survival Rate and Definition of a Risk Score for Recurrence 41
Risk factors for gastroenteropancreatic neuroendocrine neoplasms ({GEP}-{NENs}): a three-centric case{\textendash}control study 41
Neuroendocrine Tumors and Immune System 41
Vitamin D and Bone Metabolism in Adult Patients with Neurofibromatosis Type 1 41
Prognostic significance of laterality in lung neuroendocrine tumors 40
Impact of the SARS-CoV2 pandemic dissemination on the management of neuroendocrine neoplasia in Italy: a report from the Italian Association for Neuroendocrine Tumors (Itanet) 39
Neuroendocrine Neoplasms 37
Lanreotide Induces Cytokine Modulation in Intestinal Neuroendocrine Tumors and Overcomes Resistance to Everolimus 37
Interventional cytopathologist can successfully combine ultrasonographical and microscopic skills to narrow the differential diagnosis in fine‐needle aspiration of neck paraganglioma 36
Parathyroid diseases and metabolic syndrome 36
Recurrence-Free Survival in Early and Locally Advanced Large Cell Neuroendocrine Carcinoma of the Lung after Complete Tumor Resection 36
Vein wall thickness and severity of pulmonary involvement due to sars n-cov2 virus infection 35
Current understanding of pathogenetic mechanisms in neuroendocrine neoplasms 35
What Lies behind Paraneoplastic Hypercalcemia Secondary to Well-Differentiated Neuroendocrine Neoplasms? A Systematic Review of the Literature 35
Radical Resection in Entero-Pancreatic Neuroendocrine Tumors: Recurrence-Free Survival Rate and Definition of a Risk Score for Recurrence 34
Endocrine-disrupting chemicals (EDCs) and cancer: new perspectives on an old relationship 34
Calcium-stimulated calcitonin test for the diagnosis of medullary thyroid cancer: results of a multicenter study and comparison between different assays 33
Nonconventional Doses of Somatostatin Analogs in Patients with Progressing Well-Differentiated Neuroendocrine Tumor 33
Second primary neoplasms in patients with lung and gastroenteropancreatic neuroendocrine neoplasms: Data from a retrospective multi-centric study 33
Neoadjuvant Therapy for Neuroendocrine Neoplasms: Recent Progresses and Future Approaches 33
Role of Bone Metastases in Lung Neuroendocrine Neoplasms: Clinical Presentation, Treatment and Impact on Prognosis 33
Evaluation of Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR) and Systemic Immune–Inflammation Index (SII) as Potential Biomarkers in Patients with Sporadic Medullary Thyroid Cancer (MTC) 33
Natural History and Management of Familial Paraganglioma Syndrome Type 1: Long-Term Data from a Large Family 33
PRRT: identikit of the perfect patient 32
MR imaging characterization of pheochromocytoma: a comparison between typical and atypical tumor lesions 32
Laryngeal Neuroendocrine Tumor With Elevated Serum Calcitonin: A Diagnostic and Therapeutic Challenge. Case Report and Review of Literature 32
Corrigendum to: Quality of Life in Patients with Neuroendocrine Neoplasms: The Role of Severity, Clinical Heterogeneity, and Resilience (vol 106, pg e316, 2020) 32
Assessment of the Risk of Nodal Involvement in Rectal Neuroendocrine Neoplasms: The NOVARA Score, a Multicentre Retrospective Study 31
Safety and Activity of Metronomic Temozolomide in Second-Line Treatment of Advanced Neuroendocrine Neoplasms 31
Sunitinib nei feocromocitomi e paragangliomi 31
Risk of preoperative understaging of duodenal neuroendocrine neoplasms: a plea for caution in the treatment strategy 31
Dyslipidemia, lipid-lowering agents and neuroendocrine neoplasms: new horizons 30
Gender-related differences in patients with carcinoid syndrome: new insights from an Italian multicenter cohort study 29
Biliary Stone Disease in Patients with Neuroendocrine Tumors Treated with Somatostatin Analogs: A Multicenter Study 29
Case Report: Unmasking Hypercalcemia in Patients With Neuroendocrine Neoplasms. Experience From Six Italian Referral Centers 29
Endocrine Pathology 28
Association of Upfront Peptide Receptor Radionuclide Therapy With Progression-Free Survival Among Patients With Enteropancreatic Neuroendocrine Tumors 28
No phenotypic differences for polycystic ovary syndrome (PCOS) between women with and without type 1 diabetes mellitus 27
Carcinoide timico in paziente affetta da sindrome da neoplasie endocrine multiple di tipo 1 (MEN1): ruolo dello screening radiologico e medico-nucleare 27
Bone metabolism and vitamin D implication in gastroenteropancreatic neuroendocrine tumors 27
Neuroendocrine Tumors and Survival Rates in Multiple Endocrine Neoplasia Type 1 Patients: Impact of Gender Difference 26
Gestione integrata del tumore della prostata: il ruolo dell’endocrinologo 26
Selpercatinib e carcinoma midollare della tiroide 26
Nuove strategie terapeutiche per il trattamento dei NET 25
Autoimmune polyendocrinopathy-candidiasis-ectodermal-dystrophy (APECED) in Sicily: Confirmation that R203X is the peculiar AIRE gene mutation 24
Recent advances and future challenges in the diagnosis of neuroendocrine neoplasms 24
Proteasome inhibitors in medullary thyroid carcinoma: time to restart with clinical trials? 23
Gastrinomas and non-functioning pancreatic endocrine tumors in multiple endocrine neoplasia syndrome type-1 (MEN-1) 22
Targeting neuroendocrine tumors with octreotide and lanreotide: Key points for clinical practice from NET specialists 22
Clinical presentation and recurrence of pituitary neuroendocrine tumors: results from a single referral center in Colombia 21
Carcinoma showing thymus-like differentiation (CASTLE): a case report 21
Gender Differences in Lung Neuroendocrine Tumors: A Single-Center Experience 20
Immunotherapy of Neuroendocrine Neoplasms: Any Role for the Chimeric Antigen Receptor T Cells? 20
A new schedule of one week on/one week off temozolomide as second-line treatment of advanced neuroendocrine carcinomas (TENEC-TRIAL): a multicenter, open-label, single-arm, phase II trial 20
Thyroid transcription factor‐1 expression in lung neuroendocrine tumours: a gender-related biomarker? 20
Impact of dyslipidemia and lipid‐lowering therapy with statins in patients with neuroendocrine tumors 19
Editorial: Neuroendocrine tumors: the road to precision medicine 14
Authorship of Italian medical literature on neuroendocrine neoplasms: any gender gap? 14
Clinical Epigenetics of Neuroendocrine Tumors: The Road Ahead 14
Telling science and Innovation. Rare plat net 13
Metastasi ossee nei tumori neuroendocrini: presentazione clinica e terapia 13
Immune checkpoint inhibitors in cancer therapy: The leading role of the endocrinologist 12
Gender impact on pancreatic neuroendocrine neoplasm (PanNEN) prognosis according to survival nomograms 12
Totale 4.044
Salva come PNG Salva come JPEG
Categoria #
all - tutte 18.084
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 18.084
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202016 0 0 0 0 0 0 0 0 0 0 12 4
2020/202191 0 5 16 10 9 13 9 1 7 2 6 13
2021/2022215 2 0 25 3 5 14 1 6 17 16 64 62
2022/2023494 31 57 14 39 51 41 54 33 50 81 41 2
2023/2024515 20 66 53 48 40 67 17 84 3 16 69 32
2024/20252.598 108 83 25 34 104 213 327 240 173 320 971 0
Totale 4.057